06996 ANTENGENE-B
- 1.060
- +0.040+3.92%
ANTENGENE-B News
Antengene Logs Slimmer Loss in 2023 Despite Revenue Drop
Antengene's (HKG:6996) attributable loss narrowed to 581.2 million yuan, or 0.94 yuan per share, in 2023 from 601.5 million yuan, or 0.97 yuan per share, in 2022, according to the company's annual rep
德琪醫藥-B：2023 年度報告
CICC: Maintaining Hanson Pharmaceuticals' “Outperforming the Industry” Rating Target Price Raised to HK$17.81
CICC released a research report saying that maintaining the “outperforming industry” rating of Hanson Pharmaceuticals (03692), since the cooperative down payment accounting section will be confirmed in 2024 and the bank expects the company's three fees to be well controlled, the 24-year revenue and net profit forecast to be raised 2.0%/11.0% to 115.66/3.43 billion yuan, and introduced a 25-year profit forecast of 3.56 billion yuan for the first time. The target price was increased by 27.2% to HK$17.81 as the company's pipeline of innovative drugs entered the harvest period. According to the report, the company's revenue from innovative drugs and cooperative products increased to 6.87 billion yuan in 2023, accounting for 67.9%
ANTENGENE-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION AND CHANGE IN USE...
Deqi Pharmaceutical-B (06996.HK) held a board meeting on March 22 to consider and approve the annual results
Gelonghui March 11 | Deqi Pharmaceutical-B (06996.HK) announced that the company will hold a board meeting on March 22, 2024 (Friday) to consider and approve (among others) the results of the company and its subsidiaries for the year ended December 31, 2023 and their announcements.
ANTENGENE-B: NOTICE OF DATE OF BOARD MEETING
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Why We're Not Concerned Yet About Antengene Corporation Limited's (HKG:6996) 26% Share Price Plunge
Antengene Corporation Limited (HKG:6996) shares have retraced a considerable 26% in the last month, reversing a fair amount of their solid recent performance. The recent drop completes a disastrous
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Pioneer Securities Pharmaceutical's 24-year Strategy: Risks have been fully released, and subsequent industry valuations are expected to rise steadily
The Zhitong Finance App learned that Pioneer Securities released a research report saying that due to more scientific collection rules, after the collection gradually covered a large stock of generic drugs/high-value consumables, the performance was clear, and new performance growth points were formed after innovative products were launched one after another, and the drugs/device-related companies in the hospital will usher in a new growth cycle after their performance stabilizes.
Guotai Junan: The pharmaceutical industry has a low market risk appetite and selects “cost-effective” stocks with steady management
Guotai Junan released a research report saying that the high base effect in COVID-related fields dissipated throughout the year, and the growth rate is expected to gradually return to its own path, but Q1, especially in January-February, was still affected by the base effect of the epidemic.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
CITIC Construction Investment: The innovative drug sector has reached the bottom of the valuation to seize multi-line opportunities and focus on systematized pharmaceutical companies entering the harvest period
CITIC Construction Investment released a research report saying that the innovative pharmaceutical industry is expected to achieve good growth in 2024, and is optimistic about the sector's performance.
Antengene's Myeloma Medication Included in China's National Reimbursement Drug List
China's medical products administrator included Antengene's (HKG:6996) selinexor tablet for relapsed and/or refractory multiple myeloma in the country's national reimbursement drug list, a Thursday fi
Degli Pharmaceutical-B (06996), the first new drug of its kind, selinisol tablets (Sivio), was successfully included in the 2023 edition of the National Medical Insurance Drug Catalogue
Degli Pharmaceutical-B (06996) announced, the company's first new drug of its kind, celinisol tablets (trade name: Sivio
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Guotai Junan: The pharmaceutical sector valuation system has entered a small cycle of grasping business operations during a relatively stable period
The Zhitong Finance App learned that Guotai Junan released a research report saying that in 2019-2023, the collection, epidemic, etc. affected industries. It is anticipated that 2024, regardless of whether it has had the greatest positive or negative impact, has passed, returning to the main logic driven by healthcare demand.
CITIC Construction Investment Pharmaceutical's 24-year outlook: moderate growth in the industry, and multiple main lines are expected to take turns
The Zhitong Finance app learned that CITIC Construction Investment released a research report saying that it is optimistic about the pharmaceutical sector in '24 and is optimistic about opportunities for alternating performance in various main lines, such as innovation, overseas travel, improvement, and undervaluation.
Guoxin Securities's 24-year Pharmaceutical Strategy: Good Timing+High Returns, Positioning the Second Wave of Global Innovation Leaders
Guoxin Securities believes that 2023Q4 is the best time to lay out the pharmaceutical market for the next three years.
Degli Pharmaceutical-B (06996): Sivio (celinisol) and dexamethasone (Xd) were approved for listing in Macau
Jinwu Financial News | Deqi Pharmaceutical-B (06996) announced that the Macao Drug Administration has approved a new drug application (NDA) for Sivio (selinisol) combined with dexamethasone (Xd) for the treatment of adult patients with recurrent and/or refractory multiple myeloma (RRMM) who have received at least four previous treatments and are refractory to treatment with at least two proteasome inhibitors (PIs), two immunomodulators (IMIDs) and one anti-CD38 monoclonal antibody drug. Sivio is the world's first approved nuclear export protein selective XPO1 suppressor for oral administration
Analysis
Price Target
No Data
